The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.
Open accessAbstract
Angiogenesis underlies the majority of eye diseases that result in catastrophic loss of vision. Recent evidence has implicated the integrins alpha v beta 3 and alpha v beta 5 in the angiogenic process. We examined the expression of alpha v beta 3 and alpha v beta 5 in neovascular ocular tissue from patients with subretinal neovascularization from age-related macular degeneration or the presumed ocular histoplasmosis syndrome or retinal neovascularization from proliferative diabetic retinopathy (PDR). Only alpha v beta 3 was observed on blood vessels in ocular tissues with active neovascularization from patients with age-related macular degeneration or presumed ocular histoplasmosis, whereas both alpha v beta 3 and alpha v beta 5 were present on vascular cells in tissues from patients with PDR. Since we observed both integrins on vascular cells from tissues of patients with retinal neovascularization from PDR, we examined the effects of a systemically administered cyclic peptide antagonist of alpha v beta 3 and alpha v beta 5 on retinal angiogenesis in a murine model. This antagonist specifically blocked new blood vessel formation with no effect on established vessels. These results not only reinforce the concept that retinal and subretinal neovascular diseases are distinct pathological processes, but that antagonists of alpha v beta 3 and/or alpha v beta 5 may be effective in treating individuals with blinding eye disease associated with angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Self-citationIntegrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Self-citationDefinition of Two Angiogenic Pathways by Distinct α v Integrins
Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., & Cheresh, D. A. (1995) · Science · doi:10.1126/science.270.5241.1500 · Cited by 1,321
Self-citationAdamis, A. P., Miller, J. W., Bernal, M.-T., D'Amico, D. J., Folkman, J., Yeo, T.-K., & Yeo, K.-T. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75794-0 · Cited by 1,296
Aiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L., & Smith, L. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10457 · Cited by 1,260
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.
Brooks, P. C., Strömblad, S., Klemke, R., Visscher, D., Sarkar, F. H., & Cheresh, D. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118227 · Cited by 828
Self-citationCheresh, D. A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.18.6471 · Cited by 561
Self-citationKlein, R. (1994) · Archives of Ophthalmology · doi:10.1001/archopht.1994.01090210105023 · Cited by 486
Pe'er, J., Shweiki, D., Itin, A., Hemo, I., Gnessin, H., & Keshet, E. (1995) · PubMed · Cited by 422
Cited by
Benjamin, L. E., Hemo, I., & Keshet, E. (1998) · Development · doi:10.1242/dev.125.9.1591 · Cited by 1,265
Integrins in angiogenesis and lymphangiogenesis
Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2353 · Cited by 1,050
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959
Hodivala-Dilke, K. M., McHugh, K. P., Tsakiris, D. A., Rayburn, H., Crowley, D., Ullman-Culleré, M., Ross, F. P., Coller, B. S., Teitelbaum, S., & Hynes, R. O. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5487 · Cited by 740
Bader, B. L., Rayburn, H., Crowley, D., & Hynes, R. O. (1998) · Cell · doi:10.1016/s0092-8674(00)81618-9 · Cited by 647
Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor-2
Soldi, R., Mitola, S., Strasly, M., Defilippi, P., Tarone, G., & Bussolino, F. (1999) · The EMBO Journal · doi:10.1093/emboj/18.4.882 · Cited by 626
Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M., & Cheresh, D. A. (1998) · Cell · doi:10.1016/s0092-8674(00)80931-9 · Cited by 623
Self-citationEnhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins
Reynolds, L. E., Wyder, L., Lively, J. C., Taverna, D., Robinson, S. D., Huang, X., Sheppard, D., Hynes, R. O., & Hodivala-Dilke, K. M. (2002) · Nature Medicine · doi:10.1038/nm0102-27 · Cited by 613
A reevaluation of integrins as regulators of angiogenesis
Hynes, R. O. (2002) · Nature Medicine · doi:10.1038/nm0902-918 · Cited by 548
Emerging therapeutic opportunities for integrin inhibitors
Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, R. G., & Hatley, R. J. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 540
Xu, J., Rodriguez, D., Petitclerc, E., Kim, J. J., Hangai, M., Yuen, S. M., Davis, G. E., & Brooks, P. C. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200103111 · Cited by 489
NF-κB Mediates αvβ3 Integrin-induced Endothelial Cell Survival
Scatena, M., Almeida, M., Chaisson, M. L., Fausto, N., Nicosia, R. F., & Giachelli, C. M. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.4.1083 · Cited by 485
Haubner, R., Finsinger, D., & Kessler, H. (1997) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199713741 · Cited by 430
Integrin and Growth Factor Receptor Crosstalk
Eliceiri, B. P. (2001) · Circulation Research · doi:10.1161/hh2401.101084 · Cited by 395
Retinal and choroidal neovascularization
Campochiaro, P. A. (2000) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200009)184:3<301::aid-jcp3>3.0.co;2-h · Cited by 393
Campochiaro, P. A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-0993-5 · Cited by 386
Integrins as therapeutic targets
Goodman, S. L., & Picard, M. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.04.002 · Cited by 376
Stellmach, V., Crawford, S. E., Zhou, W., & Bouck, N. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.031252398 · Cited by 355
Regulation of angiogenesis by tissue factor cytoplasmic domain signaling
Belting, M., Dorrell, M. I., Sandgren, S., Aguilar, E., Ahamed, J., Dorfleutner, A., Carmeliet, P., Mueller, B. M., Friedlander, M., & Ruf, W. (2004) · Nature Medicine · doi:10.1038/nm1037 · Cited by 350
Self-citationZhang, C., Jugold, M., Woenne, E. C., Lammers, T., Morgenstern, B., Mueller, M. M., Zentgraf, H., Bock, M., Eisenhut, M., Semmler, W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1668 · Cited by 336
Noninvasive Assessment of Angiogenesis by Ultrasound and Microbubbles Targeted to α v -Integrins
Leong-Poi, H., Christiansen, J., Klibanov, A. L., Kaul, S., & Lindner, J. R. (2003) · Circulation · doi:10.1161/01.cir.0000044916.05919.8b · Cited by 334
v Integrins in Angiogenesis and Cancer
Weis, S. M., & Cheresh, D. A. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006478 · Cited by 311
Self-citationFibrosis and diseases of the eye
Friedlander, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31030 · Cited by 299
Self-citationMeyer, A., Auernheimer, J., Modlinger, A., & Kessler, H. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777947740 · Cited by 291
Forssen, E., & Willis, M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00083-5 · Cited by 287
Francis, S. E., Goh, K. L., Hodivala-Dilke, K., Bader, B. L., Stark, M., Davidson, D., & Hynes, R. O. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000016045.93313.f2 · Cited by 282
Neri, D., Carnemolla, B., Nissim, A., Leprini, A., Querzè, G., Balza, E., Pini, A., Tarli, L., Halin, C., Neri, P., et al. (1997) · Nature Biotechnology · doi:10.1038/nbt1197-1271 · Cited by 282
A human aminoacyl-tRNA synthetase as a regulator of angiogenesis
Wakasugi, K., Slike, B. M., Hood, J., Otani, A., Ewalt, K. L., Friedlander, M., Cheresh, D. A., & Schimmel, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012602099 · Cited by 270
Self-citationDifferential αv integrin–mediated Ras-ERK signaling during two pathways of angiogenesis
Hood, J. D., Frausto, R., Kiosses, W. B., Schwartz, M. A., & Cheresh, D. A. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200304105 · Cited by 262
Self-citationManipulating Angiogenesis: From Basic Science to the Bedside
Pepper, M. S. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.4.605 · Cited by 261
Mechanism of action in thalidomide teratogenesis
Stephens, T. D., Bunde, C. J. W., & Fillmore, B. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00388-3 · Cited by 259
Winter, P. M., Caruthers, S. D., Zhang, H., Williams, T. A., Wickline, S. A., & Lanza, G. M. (2008) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2008.06.003 · Cited by 166
Intravitreal CendR peptides target laser-induced choroidal neovascularization sites in mice
Puranen, J., Korhonen, S., Haugas, M., Lingasamy, P., Teesalu, T., Subrizi, A., Urtti, A., Ruponen, M., & Reinisalo, M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.025 · Cited by 10
Metadata
- Authors
- Friedlander, M., Theesfeld, C. L., Sugita, M., Fruttiger, M., Thomas, M. A., Chang, S., & Cheresh, D. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-09-03
- Volume
- 93
- Issue
- 18
- Pages
- 9764-9769
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1984038456
- Cited by
- 452
- References
- 24
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.